• 1
    Llorca PM, Chereau I, Bayle FJ et al. Tardive dyskinesias and antipsychotics: a review. Eur. Psychiatry 2002; 17: 129138.
  • 2
    Beasley CM Jr, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111123.
  • 3
    Tollefson GD, Beasley CM Jr, Tamura RN et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry 1997; 154: 12481254.
  • 4
    Beasley CM, Dellva MA, Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry 1999; 174: 2330.
  • 5
    Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry 1993; 50: 723733.
  • 6
    Benazzi F. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine. J. Clin. Psychopharmacol. 2002; 22: 438439.
  • 7
    Raedler TJ, Knable MB, Lafargue T et al. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. 1999; 90: 8190.
  • 8
    Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999; 156: 286293.
  • 9
    Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 2000; 25: 161166.